The Japanese Journal of Dermatology

Online ISSN : 1346-8146
Print ISSN : 0021-499X
ISSN-L : 0021-499X

Browse

Search
Browse

All issues

Current issue

Displaying 1-6 of 6 articles from this issue

Download citation

Show all abstracts

Seminar for Medical Education

[title in Japanese]

[in Japanese], [in Japanese]

2025Volume 135Issue 11 Pages 2287-2295
Published: October 20, 2025
Released on J-STAGE: October 20, 2025

DOIhttps://doi.org/10.14924/dermatol.135.2287

JOURNAL RESTRICTED ACCESS

Show abstractHide abstract

[in Japanese]

View full abstract

Download PDF (608K)

Original Articles

Phase III Study of Short Contact Therapy Using Benzoyl Peroxide 5% Gel on Patients with Truncal Acne Vulgaris: Single-arm, Multicenter Study

Nobukazu Hayashi, Ryoma Morikawa

2025Volume 135Issue 11 Pages 2297-2303
Published: October 20, 2025
Released on J-STAGE: October 20, 2025

DOIhttps://doi.org/10.14924/dermatol.135.2297

JOURNAL RESTRICTED ACCESS

Show abstractHide abstract

A short contact therapy using benzoyl peroxide 5% gel (BPO-5%) for truncal acne vulgaris led to a reduction in the inflammatory, non-inflammatory and total lesion counts over time. After 12 weeks, the percent of reduction were 73.27%, 60.38% and 65.16%, respectively. Adverse events related to the study drug were observed in 9 of 42 patients, all of which were mild in severity and either recovered or improved, indicating low safety concerns. The efficacy of short contact therapy with BPO-5% has been demonstrated for facial acne in randomized vehicle-controlled double-blind clinical trial, and it is expected to be useful for treating truncal acne vulgaris.

View full abstract

Download PDF (515K)
Safety and Efficacy of Tapinarof Cream in Japanese Patients with Plaque Psoriasis and Japanese Patients with Atopic Dermatitis Based on Baseline Characteristics: Additional Analysis of International Phase IIb and Japanese Phase III Studies

Atsuyuki Igarashi, Gaku Tsuji, Makiko Shimamiya, Mai Tanaka, Hiroyuki ...

2025Volume 135Issue 11 Pages 2305-2319
Published: October 20, 2025
Released on J-STAGE: October 20, 2025

DOIhttps://doi.org/10.14924/dermatol.135.2305

JOURNAL RESTRICTED ACCESS

Show abstractHide abstract

A stratified analysis of the efficacy and safety of tapinarof cream 1% was performed on the basis of data from trials in Japanese adult patients with plaque psoriasis and patients 12 years of age or older with atopic dermatitis. There was no significant difference in efficacy by age at the start of treatment, sex, or disease duration for either disease. There was also no large difference in safety by patient backgrounds described above. In addition, the proportion of patients who developed adverse events did not differ greatly by applied dose per day. There was also no tendency for the proportion of patients who developed adverse events to increase over time. These results indicate that tapinarof cream 1% is a topical drug that can be used safely for the treatment of plaque psoriasis and atopic dermatitis in many patients, irrespective of their backgrounds.

View full abstract

Download PDF (560K)

Letter to the Editor

[title in Japanese]

[in Japanese]

2025Volume 135Issue 11 Pages 2321
Published: October 20, 2025
Released on J-STAGE: October 20, 2025

DOIhttps://doi.org/10.14924/dermatol.135.2321

JOURNAL RESTRICTED ACCESS

Download PDF (111K)

Abstracts

[title in Japanese]

2025Volume 135Issue 11 Pages 2323-2328
Published: October 20, 2025
Released on J-STAGE: October 20, 2025

DOIhttps://doi.org/10.14924/dermatol.135.2323

JOURNAL RESTRICTED ACCESS

Download PDF (543K)

[title in Japanese]

2025Volume 135Issue 11 Pages 2339-2391
Published: October 20, 2025
Released on J-STAGE: October 20, 2025

DOIhttps://doi.org/10.14924/dermatol.135.2339

JOURNAL RESTRICTED ACCESS

Download PDF (2647K)

feedback

Top

Register with J-STAGE for free!